- Home
- EPC vs NVAX Comparison
EPC vs NVAX Comparison
Compare EPC & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPC
- NVAX
- Stock Information
- Founded
- EPC 1999
- NVAX 1987
- Country
- EPC United States
- NVAX United States
- Employees
- EPC N/A
- NVAX N/A
- Industry
- EPC Package Goods/Cosmetics
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EPC Consumer Discretionary
- NVAX Health Care
- Exchange
- EPC Nasdaq
- NVAX Nasdaq
- Market Cap
- EPC 1.8B
- NVAX 2.0B
- IPO Year
- EPC 2000
- NVAX 1995
- Fundamental
- Price
- EPC $35.09
- NVAX $9.00
- Analyst Decision
- EPC Buy
- NVAX Buy
- Analyst Count
- EPC 5
- NVAX 6
- Target Price
- EPC $42.40
- NVAX $17.83
- AVG Volume (30 Days)
- EPC 415.8K
- NVAX 3.6M
- Earning Date
- EPC 02-05-2025
- NVAX 11-12-2024
- Dividend Yield
- EPC 1.68%
- NVAX N/A
- EPS Growth
- EPC N/A
- NVAX N/A
- EPS
- EPC 1.97
- NVAX N/A
- Revenue
- EPC $2,253,700,000.00
- NVAX $885,193,000.00
- Revenue This Year
- EPC $2.94
- NVAX N/A
- Revenue Next Year
- EPC $2.28
- NVAX N/A
- P/E Ratio
- EPC $17.80
- NVAX N/A
- Revenue Growth
- EPC 0.09
- NVAX N/A
- 52 Week Low
- EPC $33.27
- NVAX $3.53
- 52 Week High
- EPC $41.50
- NVAX $23.86
- Technical
- Relative Strength Index (RSI)
- EPC 42.63
- NVAX 49.30
- Support Level
- EPC $35.02
- NVAX $8.13
- Resistance Level
- EPC $36.00
- NVAX $9.75
- Average True Range (ATR)
- EPC 0.90
- NVAX 0.46
- MACD
- EPC -0.23
- NVAX 0.12
- Stochastic Oscillator
- EPC 3.64
- NVAX 48.15
About EPC Edgewell Personal Care Company
Edgewell Personal Care Co is a personal-care company. The operating segments of the company include Wet Shave, Sun and Skin Care and Feminine Care. Some of the brands offered by the company include Edge, Skintimate, Personna, Schick, Carefree, Playtex, Banana Boat and Hawaiian Tropic. It derives a majority of its revenue from the United States.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.